Breast Cancer

Breast cancer treatment Arimidex granted new indication for postmenopausal women

Published in Cancer Weekly, August 9th, 2005

AstraZeneca announced that Arimidex (anastrozole) has been granted a new indication from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, which has acted as the reference member state for the European mutual recognition variation procedure leading to further approvals in five other European countries - Austria, Germany, Italy, Portugal and Spain.

The new indication - Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer - will mean that more postmenopausal women whose breast cancer is fueled by the hormone, oestrogen - about 75% of all postmenopausal cases - are now eligible to receive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-08-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry